A clinical-stage biotechnology firm based in Lille, France, 4P-Pharma, has secured $15 million in its second round.
Revital Rattenbach, CEO of 4P-Pharma, confirmed the recent funding in a press release on Monday.
4P-Pharma is a clinical-stage biotechnology business that was founded in 2014 and is headed by CEO Revital Rattenbach.
Its mission is to discover novel curative medicines for serious diseases that now lack adequate treatment. Its objective is to quickly provide patients with top-notch medications.
Through M&A and licensing-in, the firm plans to actively pursue external expansion prospects and deploy its drug regeneration strategy. Additionally, it plans to expedite its startup studio model to create a well-balanced pipeline leading up to the commercial stage.
Commenting on the news, Revital Rattenbach said: “As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year.
“This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases.”
Newsng understands that the investors in 4P-pharma are reaffirming their faith in the company’s medication regeneration concept for critical illnesses that go untreated with this cash.
They applaud the start of the two initial 4P-Pharma SPVs’ Phase 2 clinical development, which supports the strong potential of the business model of the company.
Revital Rattenbach concludes: “After a decade of existence, 4P-Pharma is opening a novel turning point of its growth.
“This successful capital-secure will enable us to push forward our patient-centric vision transforming science into success stories for the best of the patients and the whole medical community”.
We earlier reported that a first-to-market AI platform, Handl Health, has announced the success of an oversubscribed $2.5 million seed financing that was started by Everywhere VC and Mucker Capital.
